PARP inhibitors – a new treatment option for ovarian cancer
Every year, approximately, 200,000 women around the world are diagnosed with ovarian cancer.
There are usually no early signs or symptoms of the disease, and there is still no effective screening
method available for its early detection.
Currently, the standard treatment options for ovarian cancer involve a combination of surgery and
chemotherapy. Most patients with ovarian cancer initially respond well to chemotherapy; however, the majority of patients (mainly in advanced stages (III and IV)) will relapse and develop resistance to medical treatment.
Although there has been limited improvement in 5-year survival for most ovarian cancer patients over
the past three decades, the introduction of poly-ADP ribose polymerase (PARP) inhibitors as maintenance
therapy in ovarian cancer has resulted in improvements in progression-free survival and a trend toward
improved overall survival.
The aim of this brochure is to explain the the complex topic of PARP inhibitors in an easily understandable language – to provide more information on how PARP inhibitors work, which patients are eligible for treatment and what are the potential side effects.
Download your copy of the latest brochure on PARP inhibitors – a new treatment option for ovarian cancer in the following languages:
If your language is not on the list, please contact us directly or advise your local association to become ENGAGe members.